Tumor lysis syndrome (TLS) is a constellation of metabolic disturbances that may be
observed in patients with malignancies. Clinically significant TLS can occur spontaneously,
but most often is seen 48-72 h after initiation of cancer treatment. The metabolic abnormalities
observed in patients with TLS include hyperkalemia, hyperuricemia, and hyperphosphatemia,
which leads to secondary hypocalcemia. The precise incidence of TLS is not
defined, risk factors being represented by large tumor burden, neoplasms with either high
growth fraction or high sensitivity to chemotherapy, and by pre-existing impairment of renal
function. Neither racial, nor sex predilection exists. The pathogenesis of TLS is related to the
rapid tumor cell turnover or destruction, which may result in release of intracellular ions and
metabolic byproducts into the systemic circulation. Acute renal failure (ARF) may frequently
complicate TLS and is mainly due to renal tubule precipitation of uric acid, calcium
phosphate, or hypoxanthine. Hemodynamic changes reducing glomerular flow due to stillundefined
mediators are also involved in TLS pathophysiology. Pre-existing volume depletion
or renal dysfunction may worsen metabolic derangements and ARF. A good comprehension
of TLS pathophysiology has provided the basis for an effective and rational treatment of this
complication, adversely affecting the outcome of cancer patients.
Article / Publication Details
Published online: 12/3/2004
Cover Date: 2005
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISBN: 978-3-8055-7857-8 (Print)
eISBN: 978-3-318-01169-2 (Online)
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.